Editorials

Current Issue

Articles

Perspectives on the Science

Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain

A multidisciplinary summary and perspective on the CheckMate 358 trial in advanced Merkel cell carcinoma, exploring the role of dual checkpoint blockade, challenges of trial interpretation, real-world practice patterns, and evolving views on therapeutic intent and long-term outcomes.

David Michael Miller, MD, PhD, Vernon Keith Sondak, MD, Sunandana Chandra, MD, Vatche Tchekmedyian, MD, Ryan J. Sullivan, MD, Ross David Merkin, MD, Vishal Anil Patel, MD, Adewole S. Adamson, MD, MPP, Isaac Brownell, MD, PhD, Reed E. Drews, MD, Nikhil Khushalani, MD, Shailender Bhatia, MD, Paul T. Nghiem, MD, PhD

The Evolving Role of ctDNA in Merkel Cell Carcinoma: Challenges and Opportunities

This perspective discusses the evolving role of circulating tumor DNA (ctDNA) in the management of Merkel Cell Carcinoma, highlighting findings from a recent multicenter study and insights from a multi-institutional Journal Club. Key opportunities and challenges related to ctDNA’s use in surveillance and treatment decision-making are explored.

David Michael Miller, MD, PhD, Vernon Keith Sondak MD, Sunandana Chandra MD, Kenneth Y Tsai MD, PhD, Howard Lane Kaufman MD, Sameer Gupta MD, Isaac Brownell MD, PhD, Yoshine Saito, Ann W. Silk MD, Manisha Thakuria MD, Paul Nghiem MD, PhD

Comparing First-Line Immunotherapy in Advanced Melanoma: No Clear Winner?

In this Perspective on Science piece, we reflect on the indirect treatment comparison analysis between RELATIVITY-047 and CheckMate 067 trial data.

Yoshine Saito, David Michael Miller MD, PhD, Isaac Brownell MD, PhD